← Back to headlines
Travere Outlines 2026 Growth and FSGS Milestone
Travere Therapeutics has outlined its growth strategy driven by FILSPARI and a new milestone in FSGS research for 2026.
20 Feb, 01:15 — 20 Feb, 01:15
ℹOnly 1 source covers this story
